The following is an interview with Dr Ramaprasad Srinivasan, Head of the Molecular Cancer Section at the National Cancer Institute, Bethesda, USA. Dr Srinivasan talks about the genetics of type 1 and type 2 papillary kidney cancer, including the results from the CREATE trial with crizotinib, which was presented at the American Society of Clinical Oncology Genitourinary (ASCO GU) 2018 conference in San Francisco this month.

See Dr Srinivasan’s interview on Practice Update here